Search

everythinglearnresearchcommunity

for

Search:↓

Personalized multimodal treatment significantly improved hair growth and scalp coverage in androgenetic alopecia without side effects.

Androgenetic alopecia is common hair loss caused by genetics and hormones.

Hair thickness differences help diagnose hair loss severity.

8-OHdG may help diagnose and assess alopecia areata.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

The nutritional supplement Pilopeptan® WOMAN improved hair growth and thickness in women with hair loss.

The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.

Blocking a protein called prostaglandin D2 might help treat hair loss.

A protein called GIS3 is important for the growth of root hairs in Arabidopsis by controlling two genes with the help of certain growth signals.

AGA affects many, progresses differently, and early treatment is crucial.

The dietary supplement AGA-P improves the effectiveness of hair loss treatments.

Bisphenol-A (BPA) increases connections between brain cells and boosts their activity, but it blocks the effects of a male hormone on brain cell plasticity.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

α-Ketoglutaric acid improves hair growth, rabbit performance, and antioxidant levels.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Effective treatments for common hair loss are limited and may have side effects, leading to patient disappointment and treatment discontinuation.

People with androgenetic alopecia have a higher risk of heart disease.

Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.

Phospholipids help plant proteins move by regulating receptor interactions.

PRGF treatment safely and effectively helps hair loss.

Polydopamine is promising for personalized medicine and biomedical technology due to its strong adhesion and biocompatibility.

The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

AnnoPharma effectively identifies substances causing adverse drug reactions in medical abstracts.

A new AI-driven method shows promise for treating hair loss with a peptide-based drug.

The Free Androgen Index (FAI) is the best indicator of early hair loss in men before age 30.

Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.